Core Insights - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines, with significant advancements in norovirus and COVID-19 programs to be presented at the World Vaccine Congress Europe 2025 [1][2] Company Overview - Vaxart aims to enhance global public health through its innovative oral pill vaccine platform, addressing serious health challenges such as norovirus and COVID-19 [2] - The company’s proprietary delivery platform has shown the ability to generate systemic and mucosal immune responses, along with a favorable safety profile in clinical trials [2][4] - Vaxart's vaccine candidates include oral vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [4] Presentation Details - Vaxart will present two key research updates at the World Vaccine Congress: 1. Title: Oral bivalent vaccine for norovirus protection, focusing on recent improvements in immunogenicity and efficacy, presented by Dr. Sean Tucker on October 15 at 11:45 a.m. CEST [3] 2. Title: Oral Covid Vaccine - Clinical update from phase 1 to phase 2B, also presented by Dr. Sean Tucker on October 15 at 3:45 p.m. CEST [3]